BMS & Pfizer’s Eliquis Approved by FDA, Sunrise Senior Living’s Dividend: Healthcare Business Update
On Friday, the FDA approved the anti-clotting drug Eliquis (apixaban), which is an oral tablet used to decrease the risk of stroke and dangerous blood clots (systemic embolism) in patients suffering from atrial fibrillation that is not caused by a heart valve problem. The safety and efficacy of Eliquis in treating patients were evaluated in a clinical trial of more than 18,000 patients, that compared Eliquis with the anti-clotting drug warfarin. In the trial, patients using Eliquis suffered fewer strokes than those who took warfarin. The drug is manufactured Bristol-Myers Squibb Company (NYSE:BMY) and marketed by Pfizer (NYSE:PFE) and BMS.
Aeterna Zentaris (NASDAQ:AEZS) has reached an agreement with the FDA on a Special Protocol Assessment for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The acord states that the proposed trial protocol design, clinical endpoints and planned analyses are all acceptable to the FDA in support of a regulatory submission.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now>>
Health Net (NYSE:HNT) said on Friday that its subsidiaries have elected to terminate agreements with all six of Tenet Healthcare’s hospitals in Southern California, effective at midnight on December 21st. The facilities include Lakewood Regional Medical Center, Desert Regional Medical Center, Fountain Valley Hospital and Medical Center, John F. Kennedy Memorial Hospital, Los Alamitos Medical Center and Placentia Linda Hospital.
Sunrise Senior Living (NYSE:SRZ) announced today that the board of directors of a wholly owned subsidiary of Sunrise has declared a conditional special cash dividend of $2.10 per share of Sunrise common stock, with roughly $129.5 million in total, to holders of the stock as of the close on January 8th. This special cash dividend does not change the overall amount of $14.50 in cash per share being provided to stockholders, who will receive $12.40 in cash per share as merger consideration, and $2.10 as a special dividend.
Don’t Miss: Is Johnson and Johnson Still a Safe Play?